DAVID ALTSHULER - 10 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2022
Net transactions value
-$1,376,206
Form type
4
Filing time
14 Feb 2022, 15:11:13 UTC
Previous filing
03 Feb 2022
Next filing
16 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $836,369 -3,518 -5.4% $237.74 62,179 10 Feb 2022 Direct
transaction VRTX Common Stock Sale $196,727 -841 -1.4% $233.92 61,338 11 Feb 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $177,857 -757 -1.2% $234.95 60,581 11 Feb 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale $142,004 -601 -0.99% $236.28 59,980 11 Feb 2022 Direct F1, F3, F5
transaction VRTX Common Stock Sale $23,249 -98 -0.16% $237.23 59,882 11 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.36 to $234.30).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $234.95 (range $234.47 to $235.28).
F5 Open market sales reported on this line occurred at a weighted average price of $236.28 (range $235.84 to $236.74).